Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in western countries, affecting up to 20--35% of the general population[@b1], and has emerged as a major public health issue worldwide[@b2][@b3]. NAFLD has a broad spectrum of manifestations and can be histologically subdivided into simple steatosis and non-alcoholic steatohepatitis (NASH), which include steatosis, lobular inflammation and hepatocyte ballooning with or without fibrosis[@b4]. Although simple steatosis is generally considered to have a benign hepatological prognosis, NASH much more frequently progresses to fibrosis, cirrhosis and hepatocellular carcinoma in later years[@b5][@b6] and will be the leading cause of liver transplantation in the United States by 2020[@b7]. The precise mechanism responsible for the development and progression of NAFLD has not been elucidated. Some NAFLD patients will progress into NASH with cirrhosis, whereas others do not develop beyond simple steatosis. Currently, there is increasing evidence that genetic[@b8][@b9][@b10] as well as environmental factors[@b11] play important roles in the progression of NAFLD.

The human patatin-like phospholipase-3 (PNPLA3) gene is localized on human chromosome 22. The PNPLA3 protein, which is also known as adiponutrin, is expressed in both adipocytes and hepatocytes[@b12]. PNPLA3 exhibits lipase activity against triglycerides and acylglycerol transacetylase activity, and its expression is highly responsive in energy mobilization and the storage of lipid droplets[@b13]. The PNPLA3 gene is one of the potential candidate genes currently related to NAFLD susceptibility. In 1998, Romeo et al. noted that a single nucleotide polymorphism in residue 148 (I148 M, rs738409), which exhibits a C-to-G transition resulting in an amino acid substitution of isoleucine to methionine, was a strong genetic determinant of NAFLD[@b10]. Consistent with this result, some following studies also demonstrated an association between the rs738409 polymorphism and NAFLD risk[@b14][@b15][@b16]. However, it is unclear whether this polymorphism is associated with simple steatosis only or also associated with NASH. Further studies have also attempted to analyze the association between the rs738409 polymorphism and histological parameters of NAFLD[@b17][@b18][@b19], but the results are not consistent, partially because only few studies with a limited number of subjects analyzed the association between the rs738409 polymorphism and NASH or simple steatosis.

There is no approved therapy for NAFLD, and the diagnosis of NASH can only be proven by liver biopsy. In addition, it is important to establish whether the associations differ between different subgroups of NAFLD. To clarify the association between the rs738409 polymorphism and risk of NAFLD, we conducted a systematic review and meta-analysis of the available prospective studies with the specific aims of analyzing NAFLD subgroups, including simple steatosis or NASH, to clarify whether the association differed by histological parameters.

Methods
=======

Search strategy
---------------

We conducted an electronic search of the PubMed, EMBASE and Web of Science databases from their inception until December 2014 to identify the association between the rs738409 polymorphism and NAFLD risk using the following search terms: PNPLA3 and (polymorphism or variant or variation) and (NAFLD or NASH or (non-alcoholic fatty liver disease) or (fatty liver) or steatohepatitis). Additional studies not captured by our database search were identified by surveying the references of the originally identified reviews and research reports and by using the MEDLINE option "Related Articles". The search was confined to human studies without country restrictions. In addition, the publication language was restricted to English.

Inclusion and exclusion criteria
--------------------------------

Potentially relevant studies were selected based on the following inclusion criteria: (1) studies concerning the association between the *PNPLA3* rs738409 polymorphism and risk of NAFLD; (2) case-control studies based on unrelated individuals; (3) studies in which the diagnosis of NAFLD was clear; (4) studies that provide the number of NAFLD cases and controls and the frequency of the rs738409 genotypes; and (5) studies published in English. The major reasons for study exclusion were the following: (1) case-only study or overlapping data; (2) studies with a sample size less than one hundred; (3) studies with abstracts only and reports published as comment and review papers; and (4) studies with secondary causes of steatosis, including alcohol abuse, the use of drugs, surgical procedures and hepatitis B and hepatitis C virus infection.

Data extraction
---------------

Two investigators independently selected the trials and extracted the data, and disagreements or uncertainties were resolved by consensus. The following data were extracted: first author, publication year, country of origin, ethnicity of studied population, sex ratio, mean age, diagnostic criteria for NAFLD, number of individuals in the case and control groups, frequency of PNPLA3 genotypes in the cases and controls; and consistency with the Hardy-Weinberg equilibrium(HWEs).

Study quality assessment
------------------------

The quality of the studies was assessed independently by two investigators according to the quality assessment scores developed from the genetic association studies conducted by Thakkinstian et al. The total scores ranged from 0 (worst) to 13 (best)[@b20]. The criteria of the quality assessment used to analyze the studies in this meta-analysis are available in [Table S1](#s1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

The strength of the association between the PNPLA3 polymorphism and NAFLD risk was assessed by the odds ratios (ORs) and 95% confidence interval (CI). The Chi-square test was used to assess the Hardy-Weinberg equilibrium (HWE) in order to analyze the genotype distribution in the control groups. Meta-analyses were performed for four genotype contrasts per outcome: allele contrast (G versus C), dominant model (GG+CG versus CC), recessive model (GG versus CG+CC), and additive model (GG versus CC)[@b21][@b22]. The Cochrane Q statistic and the inconsistency index (I^2^) were used to calculate the heterogeneity among the studies, and a P value \< 0.10 or I^2^ \> 50% was considered to be significant[@b23]. If heterogeneity existed among the studies, the random-effect model (the Dersimonian and Laird method) was used to calculate the pooled OR. Otherwise, a fixed-effect model (the Mantel-Haenszel method) was used for outcomes without obvious heterogeneity[@b24]. Sensitivity analyses were performed to assess the stability of the results by excluding one study at a time in order to analyze the influence of each study on the overall OR. The publication bias was assessed using funnel plots and Egger\'s test[@b25].

Three subgroup analyses were additionally carried out by ethnicity (Caucasian, Asian or Hispanics), mean age (pediatric or adult) and source of the controls (hospital based or population based). The statistical analysis was performed with RevMan software version 5 (Cochrane Collaboration) and STATA software version 10.0 (Stata Corporation). A P value \< 0.05 was considered to be statistically significant in this trial unless otherwise specified.

Results
=======

Literature search
-----------------

The search strategy initially identified 419 potentially relevant articles, and 363 articles were determined to be irrelevant after a review of the titles and abstracts. Thus, 56 trials proceeded to a full-text review, and an additional 33 studies were excluded. Finally, 23 articles were ultimately selected for inclusion in the meta-analysis[@b17][@b18][@b19][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45]. A flow describing the article selection process for this meta-analysis is shown in [Figure 1](#f1){ref-type="fig"}. Of all of the studies included, 10 studies involved Caucasians[@b17][@b19][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b42], 12 studies investigated Asians[@b18][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b43][@b44][@b45], and 1 study researched Hispanics[@b41]. All of the studies followed a case-control design, 8 studies used population-based controls[@b16][@b18][@b28][@b33][@b40][@b41][@b42][@b43], and 15 studies used hospital-based controls[@b17][@b19][@b26][@b29][@b30][@b31][@b32][@b34][@b35][@b36][@b37][@b38][@b39][@b44][@b45]. In addition, 19 studies were conducted in adult patients[@b16][@b17][@b18][@b19][@b26][@b28][@b29][@b30][@b31][@b32][@b34][@b35][@b36][@b37][@b38][@b39][@b42][@b44][@b45], and 4 investigated pediatric patients[@b33][@b40][@b41][@b43]. The distribution of genotypes in the controls was consistent with HWE in 21 studies[@b17][@b18][@b19][@b26][@b27][@b29][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45] and insufficient in the 2 other studies[@b28][@b30]. The quality score of the included studies ranged from 7 to 11 ([Table S1](#s1){ref-type="supplementary-material"}). The characteristics of the included studies are presented in [Table 1](#t1){ref-type="table"}.

Association between rs738409 and risk for NAFLD
-----------------------------------------------

### All studies

A total of 23 studies with 6071 cases and 10366 controls reported an association between the rs738409 polymorphism and NAFLD risk[@b17][@b18][@b19][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41]. Overall, the frequency of the G allele was 49.5% in NAFLD and 34.8% in the controls. The Hispanic population bears the highest frequency of the G allele (69.0% cases vs. 41.9% controls), followed by the Asian (54.2% cases vs. 39.9% controls) and Caucasian (42.2% cases vs. 22.7% controls) populations. The distribution of the rs738409 genotypes and alleles is presented in [Table 2](#t2){ref-type="table"}. Strong evidence of an association between the rs738409 polymorphism and NAFLD risk was found in all genetic models: allele contrast (OR = 2.10, 95% CI = 1.78--2.48, P \< 0.00001; heterogeneity test: I^2^ = 89%, P \< 0.00001); dominant model (OR = 2.06, 95% CI = 1.75--2.43, P \< 0.00001; heterogeneity test: I^2^ = 67%, P \< 0.00001); recessive model (OR = 2.49, 95% CI = 2.01--3.08, P \< 0.00001; heterogeneity test: I^2^ = 72%, P \< 0.0001); and additive model (OR = 3.41, 95% CI = 2.57--4.52, P \< 0.00001; heterogeneity test: I^2^ = 77%, P \< 0.00001) ([Figure 2](#f2){ref-type="fig"}). After exclusion of the two articles deviating from HWE in the cases and controls, the results of the relationship was not influenced significantly in all genetic models ([Table 3](#t3){ref-type="table"}).

### Subgroup analyses

Subgroup analyses were conducted to explore the differences between ethnicity, mean age and sources of the controls. In the subgroup analysis by ethnicity, significant association was found between the rs738409 polymorphism and NAFLD risk among the Caucasian, Asian and Hispanic populations. The association between rs738409 polymorphism and NAFLD was most significant in Hispanic population, which followed by Caucasian population, and the association was weakest in Asian population. The analyses also showed that the risk of NAFLD was significantly increased in both adult participants and pediatric subjects. In addition, the G allele was strongly associated with NAFLD susceptibility in hospital-based controls and population-based controls. The results were consistent in all genetic models. More details are presented in [Table 3](#t3){ref-type="table"}.

Histological Severity of NAFLD
------------------------------

Five eligible studies were used to investigate the association between the rs738409 polymorphism and lobular necroinflammation, including 1978 patients. A statistically significant association was seen between carrying GG genotype and higher inflammation scores (OR = 3.13, 95% CI = 2.76--3.56, P \< 0.00001; heterogeneity test: I^2^ = 0%, P = 0.674) with obvious publication bias (Egger test: P = 0.980) ([Figure 3](#f3){ref-type="fig"}). The six eligible studies with 2552 patients analyze the relationship between rs738409 polymorphism and fibrosis. The analysis pointed out that the GG genotype was significantly associated with fibrosis score (OR = 3.11, 95% CI = 2.66--3.65, P \< 0.00001; heterogeneity test: I^2^ = 18.3%, P = 0.295) and the publication bias was not significant (Egger test: P = 0.457) ([Figure 3](#f3){ref-type="fig"}).

Association between rs738409 and risk for simple steatosis
----------------------------------------------------------

Overall, 7 studies with 387 cases and 2306 controls analyzed the rs738409 polymorphism and risk of simple steatosis[@b17][@b18][@b19][@b28][@b32][@b34][@b36]. Interestingly, the frequency of the risk G allele was very close between the cases (38.1%) and controls (38.0%). In Caucasian subjects, the frequency of the G allele was 34.3% in cases and 23.2% in controls, and these values are lower than those found in the Asian population (44.3% cases vs. 42.3% controls) ([Table 4](#t4){ref-type="table"}). We analyzed the relationship between the G allele and the risk of simple steatosis. No significant association was observed between rs738409 polymorphism and simple steatosis under additive model (OR = 1.34, 95% CI = 0.82--2.20, P = 0.25; heterogeneity test: I^2^ = 0%, P = 0.58), dominant model and recessive model ([Figure 4](#f4){ref-type="fig"}). However, a significant association was found in allele contrast. A further subgroup analysis based on ethnicity showed no obvious association between the rs738409 polymorphism and simple steatosis in Asian subjects, while a strong association was found in the Caucasian population under the allele contrast instead of the other three genetic models. ([Table 5](#t5){ref-type="table"}).

Association between rs738409 and NASH risk
------------------------------------------

Overall, seven studies with 1466 cases and 2306 controls reported the rs738409 polymorphism and risk of NASH[@b17][@b18][@b19][@b28][@b32][@b34][@b36]: four studies conducted in Caucasians and three studies performed in Asian populations. The pooled overall frequency of the risk G allele was 53.5% in the cases and 38.0% in the controls. The G allele varied widely between the different populations: high in the Asian populations (60.9% cases vs.42.3% controls) and lower in the Caucasian subjects (45.9% cases vs. 23.2% controls) ([Table 4](#t4){ref-type="table"}). Strong evidence of an association was detected between the rs738409 polymorphism and NASH risk under the additive model (OR = 4.44, 95% CI = 3.39--5.82, P \< 0.00001; heterogeneity test: I^2^ = 0%, P = 0.49) ([Figure 5](#f5){ref-type="fig"}). The association was also significant in the other three genetic models, and no evidence of heterogeneity was observed between the studies. Evidence of a strong association between the rs738409 polymorphism and NASH susceptibility was also found in both Asian and Caucasian populations with all genetic models. In addition, Caucasian populations with rs738409 polymorphism are more easily develop into NASH than Asian populations. The results are described in [Table 6](#t6){ref-type="table"}.

Sensitivity and Publication Bias
--------------------------------

Sensitivity analysis was performed under additive model to evaluate the influence of a specific study on the overall estimate. The corresponding pooled ORs with 95% CIs produced similarly before and after omitting each study at a time, indicating that our results were stable and reliable ([Table S2](#s1){ref-type="supplementary-material"}). The funnel plots of the studies were symmetric in the current meta-analysis ([Figure 6](#f6){ref-type="fig"}). Furthermore, the results of Egger\'s test did not support the existence of publication bias (additive model: NAFLD: P = 0.467; SS: P = 0.611; NASH: P = 0.282).

Discussion
==========

The current meta-analysis provided a systematic assessment of the association between the PNPLA3 rs738409 polymorphism and susceptibility to NAFLD, including its subtypes simple steatosis and NASH. Our results suggested that rs738409 polymorphism exerted a significant influence not only on NAFLD risk, but also on histological severity of NAFLD. In addition, a further analysis showed that individuals with the rs738409 polymorphism experienced a significantly increased risk for NASH. However, our meta-analysis did not show a definite association of rs738409 polymorphism with simple steatosis.

Our results are consistent with those from a previous meta-analysis conducted by Sookoian et al.[@b14], which showed a significant association between the rs738409 polymorphism and NAFLD (OR = 3.26, 95% CI = 2.73--3.89, P \< 0.00001) and a significant association between the rs738409 polymorphism and NASH (OR = 3.26, 95% CI = 2.14--4.95, P \< 0.00001), similar to the results reported in this manuscript. In the present meta-analysis, analysis of the rs738409 polymorphism revealed a significantly increased NAFLD risk in all genetic models. When the data were stratified by subject ethnicity, a significant correlation was found in all three populations, suggesting that the susceptibility genes may be a strong indicator across different races. In the population-based and hospital-based control studies, a significant correlation was also observed in all genetic models, suggesting that our results were not influenced by the source of controls. In addition, the association between the rs738409 polymorphism and NAFLD risk was also significant in both adult and children populations, indicating that the results are highly stable and not influenced by ethnicity, source of the controls and age of participants.

A large population-based study that involved 9229 multiethnic population, including African-Americans, Hispanics and European-Americans, revealed that patients with the rs738409 polymorphism are associated with a higher risk of NAFLD compared with normal controls[@b10]. These findings are generally consistent with individual published reports because 70--90% of the trials showed an association between the rs738409 polymorphism and NAFLD risk[@b27][@b38][@b41]. The underlying mechanism for how PNPLA3 genotype increases NAFLD susceptibility remains to be elucidated. The questions that have been raised are whether the I148M polymorphism increases liver damage favoring the accumulation of fatty acids in lipid droplets or increases the susceptibility to progress into NASH and fibrogenesis.

It should be noted that rs738409 polymorphism was only significantly associated with increased simple steatosis risk under allelic model, but not under the other three genetic models. When stratified by ethnicity, we only detect a significant association in the Asian subgroup under allele contrast, but failed to detect a significant association in the Caucasion population under all genetic models. This meta-analysis of the associations of the rs738409 polymorphism with NASH showed a significant relation. In the subgroup analysis stratified by ethnicity, similar correlations were observed in both Caucasian and Asian populations. The results from the allele contrast were consistent with those from the other genetic models. The sensitivity analysis revealed that no single study qualitatively changed the pooled odds ratios. These findings suggested that rs738409 polymorphism was strongly associated with NASH.

In our meta-analysis, it appears that the rs738409 polymorphism is more likely to increase the NASH risk instead of simple steatosis. Consistent with our results, animal studies have revealed that, although PNPLA3 has triglyceride lipase activity and is responsible for the transalkylation of acylglycerol, knockout of PNPLA3 has no effect on liver steatosis or insulin resistance[@b46]. Further epidemiological studies have also noted that this G allele variation did not affect the main risk factors for steatosis, including insulin resistance, LDL, HDL, total cholesterol and glucose levels[@b29]. Other polymorphisms, such as CD14 rs2569190 and GCLC rs4140528, are also regarded to increase the risk of NASH instead of simple steatosis[@b47]. There are some possible reasons to explain this phenomenon. First, the effect of the rs738409 G allele may be involved in the differential expression and function of variant PNPLA3 instead of resulting in a loss of function of the wild-type protein. Second, there may be some gene-gene interactions. It is possible that the difference in phenotypes may be caused by some other genetic variant that is strongly linked to rs738409. Third, although NASH and simple steatosis are currently regarded as two histological subtypes along the unique spectrum of NAFLD, evidence suggests that these two conditions may be not only different from the histological syndrome but also varied from pathophysiological standpoints. The results that the association between NASH risk and the rs738409 genotype is independent of simple steatosis might suggest that simple steatosis may not be the essential condition for the progressive damage. Simple steatosis and NASH are likely to be two independent conditions in the NAFLD spectrum.

Despite the inevitable limitations of this meta-analysis, we believe that our research provides useful information. First, the individual sample size of each study included in our meta-analysis was too small to obtain a definite association between rs738409 polymorphisms and NAFLD risk, but the pooled odds ratios generated from the 23 studies significantly increased the statistical power of the analysis compared to that obtained with a single study. Moreover, the protocol of this meta-analysis has been well-designed with explicit criteria and methods for study selection, data extraction and data analysis, which allowed reliable inferences about causality. Third, there was no significant publication bias in this meta-analysis, and the results of the sensitivity analysis support the stability of the results.

However, some limitations of this meta-analysis should be addressed. First, the retrieved literature may not be sufficiently comprehensive. Only published case-control studies were included in this meta-analysis. Second, most of the study subjects were of Caucasian and Asian ancestry, and the Hispanic subgroup was very limited in this meta-analysis. Thus, potential selective bias and publication bias may have occurred. Third, because NAFLD was a multifactor disease, the potential effects of gene-gene and gene-environment interactions should be considered. Fourth, the sample size of NASH in this meta-analysis was so small that the statistical power for making a definitive conclusion regarding the possible risk of the rs738409 polymorphism was limited.

In conclusion, results from this meta-analysis showed that the G allele at PNPLA3 gene was a risk factor for NAFLD and its subtype NASH, especially in Asian, Caucasian and Hispanic populations. However, no association was observed between the rs738409 polymorphism and simple steatosis risk. Further studies with higher quality, more participants and various ethnicities are needed to obtain a more precise estimate of the genetic effects.
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###### Characteristics of Studies Included in this meta-analysis

  Author               Year    Country or Region     Ethnicity   Source of Control    Genotyping method       Age              Female n (%)            NAFLD diagnosis   Liver Biopsy(n)   Cases   Controls   Quality Score
  ------------------- ------ ---------------------- ----------- ------------------- --------------------- ----------- ------------------------------- ----------------- ----------------- ------- ---------- ---------------
  Kantartzis et al.    2009         Germany          Caucasian          H-B                TaqMan            Adult               200(60.6)                  H-MRS              NA           105      225           10
  Sookoian et al.      2009        Argentina         Caucasian          H-B          Allele specific PCR     Adult               186(69.9)                US and LB            103          172       94           10
  Valenti et al.       2010   Italy/United Kingdom   Caucasian          P-B                TaqMan            Adult     Italy: 114(26.3) UK: 123 (38)         LB                574          574      179           11
  Rotman et al.        2010           USA            Caucasian          P-B          MassARRAY Sequenome     Adult                  NA                       LB                766          120      766            7
  Speliotes et al.     2010           USA            Caucasian          H-B          MassARRAY Sequenome     Adult                  NA                       LB                678          678      1405          10
  Goran et al.         2010           USA            Hispanic           P-B                TaqMan          Pediatric            129 (68.6)                  DEXA               NA           71       188            9
  Lin et al.           2010          Taiwan            Asian            P-B                TaqMan          Pediatric            174 (33.5)                   US                NA           102      418           11
  Hotta et al.         2010          Japan             Asian            H-B                TaqMan            Adult              527 (63.4)                   LB                253          253      575            8
  Wang et al.          2011          Taiwan            Asian            H-B                TaqMan            Adult              472 (53.7)                   US                NA           156      723           10
  Petit et al.         2011          France          Caucasian          H-B             Real-time PCR        Adult              120 (51.3)                  H-MRS              NA           149       85            8
  Zain et al.          2012         Malaysia           Asian            H-B                TaqMan            Adult              180 (52.6)                   LB                144          144      198           10
  Kawaguchi et al.     2012          Japan             Asian            H-B               BeadChip           Adult              741 (50.7)                   LB                529          529      932           10
  Valenti et al.       2012         Italian          Caucasian          H-B             Real-time PCR        Adult               87 (21.7)                   LB                144          144      257            9
  Li et al.            2012          China             Asian            H-B                TaqMan            Adult                  NA                       US                NA           203      202           10
  Peng et al.          2012          China             Asian            H-B          MassARRAY Sequenome     Adult              308 (27.8)                   US                NA           553      553           11
  Lin et al.           2013          Taiwan            Asian            P-B                TaqMan          Pediatric            237 (30.3)                   US                NA           182      599            9
  Guichelaar et al.    2013           USA            Caucasian          H-B                TaqMan            Adult              122 (84.7)                   LB                144          132       12            8
  Verrijken et al.     2013         Belgium          Caucasian          H-B                TaqMan            Adult              331 (70.4)                   LB                287          208       79           10
  Kitamoto et al.      2013          Japan             Asian            P-B               BeadChip           Adult              782 (49.6)                   LB                564          564      1946          11
  Musso et al.         2013          Italy           Caucasian          P-B                TaqMan            Adult               78 (36.8)                   US                NA           51       161           11
  Lin et al.           2014          Taiwan            Asian            P-B                TaqMan          Pediatric            242 (30.4)                   US                NA           191      606           11
  Niu et al.           2014          China             Asian            H-B             ABI Sequencer        Adult              426 (53.3)                   US                NA           390      409           10
  Lee et al.           2014          Korea             Asian            H-B                TaqMan            Adult              178 (52.5)                   US                NA           155      184           11

P-B, population-based study; H-B, hospital-based study; H-MRS: hydrogen magnetic resonance (H-MR) spectroscopy, US: liver ultrasonographic examination, LB: liver biopsy, DEXA: dual energy-ray absorptiometry, NA: not available.

###### The distribution of alleles and genotypes of PNPLA3 in NAFLD studies

                  Sample size   Genotype in cases   Genotype in controls   Case   Control   G allele (%)   C allele (%)                                                             
  -------------- ------------- ------------------- ---------------------- ------ --------- -------------- -------------- ----- ----- ----- ----- ------ ------ ------ ------ ------ ------
  Kantartzis          105              225                   13             41      51           18             70        137   67    143   106   344    31.9   23.6   68.1   76.4   YES
  Sookoian            103              94                    NA             NA      NA           NA             NA        NA    130   76    63    125    63.1   33.6   36.9   66.4   YES
  Valenti 2010        574              179                   75            254      245          5              56        118   404   744   66    292    35.2   18.4   64.8   81.6   0.59
  Rotman              520              336                   NA             NA      NA           NA             NA        NA    516   524   153   519    49.6   22.8   50.4   77.2    NA
  Speliotes           592             1405                   NA             NA      NA           NA             NA        NA    592   592   618   2192    50    22.0    50    78.0   YES
  Goran               71               188                   34             30       7           19             60        38    98    44    98    136     69     26     31     74    0.56
  Lin 2011            102              418                   26             52      24           59            192        167   104   100   310   526    51.0   37.1   49.0   62.9   0.75
  Hotta               253              575                  175             97      111         104            296        175   305   201   504   646    88.3   43.8   11.7   56.2   0.28
  Wang                156              723                   40             80      36          269            335        119   152   160   573   873    51.3   60.4   48.7   39.6   0.40
  Petit               149              85                    NA             NA      68           NA             NA        51    NA    NA    NA     NA     NA     NA     NA     NA     NA
  Zain                144              198                   NA             NA      NA           NA             NA        NA    130   158   95    301    45.1   24.0   54.9   76.0   YES
  Kawaguchi           529              932                  217            468      247         203            236        88    642   412   902   962    85.2   34.4   14.8   65.6   0.17
  Valenti 2012        144              257                   21             68      55           16             95        146   110   178   127   387    38.2   24.7   61.8   75.3   0.92
  Li                  203              202                   49             84      70           18             90        94    182   224   126   278    44.8   31.0   55.2   69.0   0.59
  Peng                553              553                   93            276      183          59            259        235   462   642   377   729    41.8   34.1   58.2   65.9   0.32
  Lin 2013            182              599                   35             93      54           74            288        237   163   201   436   762    44.8   36.4   55.2   63.6   0.35
  Guichelaar          132              12                    12             41      79           0              3          9    65    199    3     21    24.6   12.5   75.4   87.5   0.62
  Verrijken           208              79                    17             83      108          0              23        56    117   299   140   434    20.4   5.5    79.6   94.5   0.13
  Kitamoto            564             1946                  227            241      96          199            513        300   695   433   911   1113   61.6   23.4   38.4   76.6   0.44
  Musso               51               161                   14             23      14           21             49        91    51    51    91    231     50    28.3    50    71.7   YES
  Lin                 191              606                   38             95      58           75            293        238   171   211   443   769    44.8   36.6   55.2   63.4   0.30
  Niu                 390              409                  189            153      48           50            176        183   531   249   276   542    68.1   33.7   31.9   66.3   0.45
  Lee                 155              184                   49             75      31           37             92        55    173   137   166   202    55.8   45.1   44.2   54.9   0.90

NA: not applicable YES: studies have already pointed out that the data was HWE, but the data was not applicable.

###### Association between PNPLA3 polymorphism and NAFLD risk

  Subgroup                     Inherited model   Study number   NO. of cases/controls(n/n)   P~heterogeneity~   I^2^ (%)   Pooled OR (95%CI)    P value[a](#t3-fn1){ref-type="fn"}
  --------------------------- ----------------- -------------- ---------------------------- ------------------ ---------- -------------------- ------------------------------------
  Total studies                Allele contrast        22               11838/18552             P \< 0.00001        89      2.10 (1.78, 2.48)               P \< 0.00001
                               Dominant model         19                4709/7328              P \< 0.0001         67      2.06 (1.75, 2.43)               P \< 0.00001
                               Recessive model        18                4560/7243              P \< 0.0001         72      2.49 (2.01, 3.08)               P \< 0.00001
                               Additive model         18                2523/3886              P \< 0.00001        77       3.41 (2.57,4.52)               P \< 0.00001
  Studies excluded for DHWE                                                                                                                                      
                               Allele contrast        21               10798/17880             P \< 0.00001        89      2.05 (1.74, 2.42)               P \< 0.00001
                               Dominant model         18                4560/7243              P \< 0.00001        69      2.02 (1.84, 2.20)               P \< 0.00001
                               Recessive model        18                4560/7243              P \< 0.00001        72      2.51 (2.28, 2.77)               P \< 0.00001
                               Additive model         18                2523/3886              P \< 0.00001        77      3.32 (2.94, 3.74)               P \< 0.00001
  Ethnicity                                                                                                                                                      
  Caucasian                    Allele contrast        9                 4858/5496              P \< 0.0001         75      2.56 (2.06, 3.18)               P \< 0.00001
                               Dominant model         7                  1363/998                P = 0.60          0       2.21 (1.83, 2.67)               P \< 0.00001
                               Recessive model        6                  1214/913                P = 0.35          10      2.68 (1.78, 4.05)               P \< 0.00001
                               Additive model         6                  704/617                 P = 0.27          22      3.79 (2.35, 6.13)               P \< 0.00001
  Asian                        Allele contrast        12                6838/12822             P \< 0.00001        88       1.82 (1.52,2.18)               P \< 0.00001
                               Dominant model         11                3275/6213              P \< 0.00001        78      1.95 (1.56, 2.43)               P \< 0.00001
                               Recessive model        11                3275/6213              P \< 0.00001        81      2.33 (1.81, 2.99)               P \< 0.00001
                               Additive model         11                1778/3212              P \< 0.00001        84      3.08 (2.21, 4.31)               P \< 0.00001
  Hispanics                    Allele contrast        1                  142/234                    NA             NA      3.09 (1.99, 4.80)               P \< 0.00001
                               Dominant model         1                   71/117                    NA             NA      4.40 (1.84, 10.51)               P = 0.0009
                               Recessive model        1                   71/117                    NA             NA      4.74 (2.41, 9.33)               P \< 0.00001
                               Additive model         1                   41/57                     NA             NA      9.71 (3.64, 25.94)              P \< 0.00001
  Control source                                                                                                                                                 
  Population based             Allele contrast        7                 4076/5836              P \< 0.00001        90      2.17 (1.60, 2.95)               P \< 0.00001
                               Dominant model         7                 2038/2918              P \< 0.00001        82      2.47 (2.14, 2.85)               P \< 0.00001
                               Recessive model        7                 2038/2918              P \< 0.00001        83       3.04 (2.00,4.62)               P \< 0.00001
                               Additive model         7                 1139/1542              P \< 0.00001        87      4.61 (2.58, 8.23)               P \< 0.00001
  Hospital based               Allele contrast        15                7762/12716             P \< 0.00001        89      2.07 (1.68, 2.54)               P \< 0.00001
                               Dominant model         12                2671/4410                P = 0.65          0        1.76 (1.57,1.97)               P \< 0.00001
                               Recessive model        11                2522/4325                P = 0.26          19      2.10 (1.78, 2.47)               P \< 0.00001
                               Additive model         11                1384/2344                P = 0.34          11      2.62 (2.20, 3.13)               P \< 0.00001
  Age of participants                                                                                                                                            
  Adult                        Allele contrast        18               10746/15072             P \< 0.00001        90      2.19 (1.82, 2.62)               P \< 0.00001
                               Dominant model         15                4163/5588              P \< 0.0001         70      2.10 (1.74, 2.54)               P \< 0.00001
                               Recessive model        14                4014/5503              P \< 0.00001        75      2.59 (2.01, 3.34)               P \< 0.00001
                               Additive model         14                2248/2978              P \< 0.00001        79      3.54 (2.54, 4.94)               P \< 0.00001
  Pediatric                    Allele contrast        4                 1092/3480                P = 0.01          73      1.73 (1.31, 2.29)                P = 0.0001
                               Dominant model         4                  546/1740                P = 0.09          54      1.89 (1.34, 2.66)               P \< 0.00001
                               Recessive model        4                  546/1740                P = 0.07          58      2.18 (1.47, 3.22)               P \< 0.0001
                               Additive model         4                  275/908                 P = 0.03          66      2.97 (1.75, 5.02)               P \< 0.0001

a: Test for overall effect. NA: Not applicable.

###### The distribution of alleles and genotypes of PNPLA3 in SS studies and NASH studies

                Sample size   Genotype in cases   Genotype in controls   Case   Control   G allele (%)   C allele (%)                                                         
  ------------ ------------- ------------------- ---------------------- ------ --------- -------------- -------------- ----- ------ ------ ------ ------ ------ ------ ------ ------
  **SS**                                                                                                                                                                         
  Sookoian          40               94                    NA             NA      NA           NA             NA        NA     42     38     63    125    52.5   33.6   48.5   66.4
  Rotman            82               336                   NA             NA      NA           NA             NA        NA     85     79    153    519    51.8   22.8   48.2   77.2
  Hotta             64               575                   19             26      19          104            296        175    64     64    504    646     50    43.8    50    56.2
  Zain              33               198                   NA             NA      NA           NA             NA        NA     23     43     95    301    35.0   24.0   65.0   76.0
  Guichelaar        60               12                    4              13      43           0              3          9     21     99     3      21    17.5   12.5   82.5   87.5
  Verrijken         57               79                    1              14      42           0              23        56     16     98     23    135    14.0   14.6   86.0   85.4
  Kitamoto          51              1012                   10             24      17          199            513        300    44     58    911    1113   43.1   45.0   56.9   55.0
  Total             387             2306                   34             77      121         303            835        540   295    479    1752   2860   38.1   38.0   61.9   62.0
  **NASH**                                                                                                                                                                       
  Sookoian          63               94                    NA             NA      NA           NA             NA        NA     88     38     63    125    69.8   33.6   30.2   66.4
  Rotman            438              336                   NA             NA      NA           NA             NA        NA    431    445    153    519    49.2   22.8   45.8   77.2
  Hotta             189              575                   78             85      26          104            296        175   241    137    504    646    63.8   43.8   36.2   56.2
  Zain              111              198                   NA             NA      NA           NA             NA        NA    106    116     95    301    48.0   24.0   52.0   76.0
  Guichelaar        72               12                    8              28      36           0              3          9     44    100     3      21    30.6   12.5   69.4   87.5
  Verrijken         151              79                    16             69      66           0              23        56    101    201     23    135    33.4   14.6   66.6   85.4
  Kitamoto          442             1012                  187            183      72          199            513        300   557    327    911    1113   63.0   45.0   37.0   55.0
  Total            1466             2306                  289            365      200         303            835        540   1568   1364   1752   2860   53.5   38.0   46.5   62.0

SS: simple steatosis; NASH: nonalcoholic steatohepatitis.

###### Association between PNPLA3 polymorphism and simple steatosis risk

  Group              Study number(n)   NO. of cases/controls(n/n)   P~heterogeneity~   I^2^ (%)   Pooled OR (95%CI)    P value[a](#t5-fn2){ref-type="fn"}
  ----------------- ----------------- ---------------------------- ------------------ ---------- -------------------- ------------------------------------
  **SS**                                                                                                                                
  Allele contrast           7                   774/4612              P \< 0.0001         81      1.59 (1.02, 2.49)                 P = 0.04
  Dominant model            4                   232/1678                P = 0.94          0       0.94 (0.66, 1.33)                 P = 0.73
  Recessive model           4                   232/1678                P = 0.49          0       1.49 (0.97, 2.30)                 P = 0.07
  Additive model            4                   155/843                 P = 0.58          0       1.34 (0.82, 2.20)                 P = 0.25
  **Caucasian**                                                                                                                         
  Allele contrast           4                   478/1042               P = 0.005          76      1.98 (1.05, 3.75)                 P = 0.04
  Dominant model            2                    117/91                 P = 0.71          0       0.93 (0.48, 1.82)                 P = 0.84
  Recessive model           2                    117/91                 P = 0.74          0       2.77 (0.30, 25.51)                P = 0.37
  Additive model            2                    90/65                  P = 0.75          0       2.69 (0.29, 24.94)                P = 0.38
  **Asian**                                                                                                                             
  Allele contrast           3                   296/3570                P = 0.20          37      1.22 (0.89, 1.67)                 P = 0.22
  Dominant model            2                   115/1587                P = 0.62          0       0.94 (0.62, 1.42)                 P = 0.77
  Recessive model           2                   115/1587                P = 0.16          49      1.44 (0.93, 2.25)                 P = 0.10
  Additive model            2                    65/778                 P = 0.23          30      1.28 (0.77, 2.14)                 P = 0.35

SS: simple steatosis.

a: Test for overall effect.

###### Association between PNPLA3 Polymorphism and NASH risk

  Group              Study number(n)   NO. of cases/controls(n/n)   P~heterogeneity~   I^2^ (%)    Pooled OR (95%CI)     P value[a](#t6-fn1){ref-type="fn"}
  ----------------- ----------------- ---------------------------- ------------------ ---------- ---------------------- ------------------------------------
  **NASH**                                                                                                                                
  Allele contrast           7                  2932/4612               P = 0.005          68       2.78 (2.24, 3.44)                P \< 0.00001
  Dominant model            4                   854/1678                P = 0.63          0        2.44 (1.95, 3.04)                P \< 0.00001
  Recessive model           4                   854/1678                P = 0.63          0        3.15 (2.58, 3.85)                P \< 0.00001
  Additive model            4                   489/843                 P = 0.49          0        4.44 (3.39, 5.82)                P \< 0.00001
  **Caucasian**                                                                                                                           
  Allele contrast           4                  1448/1042                P = 0.59          0        3.40 (2.82, 4.09)                P \< 0.00001
  Dominant model            2                    223/91                 P = 0.95          0        3.11 (1.82, 5.33)                P \< 0.0001
  Recessive model           2                    223/91                 P = 0.38          0       10.33 (1.42, 75.06)                 P = 0.02
  Additive model            2                    126/65                 P = 0.36          0       14.28 (1.96, 103.92)               P = 0.009
  **Asian**                                                                                                                               
  Allele contrast           3                  1484/3570                P = 0.24          30       2.26 (1.93, 2.65)                P \< 0.00001
  Dominant model            2                   631/1587                P = 0.38          0        2.33 (1.83, 2.96)                P \< 0.00001
  Recessive model           2                   631/1587                P = 0.79          0        3.05 (2.49, 3.74)                P \< 0.00001
  Additive model            2                   363/778                 P = 0.41          0        4.22 (3.21, 5.55)                P \< 0.00001

a: Test for overall effect.
